Browse a selection of key resources and publications about our pipeline.

2025 WCLC REZILIENT2

2025 WCLC REZILIENT1

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab (2025 JCO)

Efficacy of Zipalertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutations Who Received Prior Platinum-Based Chemotherapy With or Without Amivantamab (2025 ASCO)

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study of CLN-049 for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease (2024 ASH)

CLN-978: Mechanism of Action: T Cell Engagers

Mechanism of Action: T Cell Engagers

Modulating the Immune System: An Intricate Balancing Act

Advances in Autoimmune Diseases: A Conversation with Dr. Ricardo Grieshaber-Bouyer

CLN-978, A CD19-Directed T-Cell Engager (TCE), Leads to Rapid and Deep B-Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases (2024 ACR)